Home » News » CROs/Service Providers » Charles River and Metabolon partner on cancer research

Charles River and Metabolon partner on cancer research

Friday, April 6, 2012

Charles River Discovery Services is partnering with Metabolon, a diagnostic products and services company based in Research Triangle Park, N.C., to enhance oncology research.

The collaboration will draw on Metabolon’s in-depth analysis of metabolic data to identify both mechanism of action and biomarkers, which Charles River will combine with its preclinical oncology study expertise.

Working together, Metabolon and Charles River can provide:

  • MOA: elucidation, identification, characterization and validation of drug target candidates
  • Expertise in preclinical studies using validated in vivo and in vitro models
  • PK/PD, tumor growth delay, tumor growth inhibition, survival, combination and adjuvant study designs
  • Assessment of lead chemistries, lead ID, optimal dose, optimal combinations, sensitivity/resistance patterns and new indications for existing compounds
  • Development of biomarkers for preclinical PD, patient stratification/selection, translational models and efficacy

The new partnership will officially be announced at the upcoming American Association for Cancer Research (AACR) meeting.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!